Publication | Open Access

652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)

Tumor BiologyMedicinePharmacologyPathologyPreliminary Clinical ActivityCancer BiologyCancer TreatmentOncologyLung CancerCancer ResearchTri-complex Ras-multi